| Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis D Adams, A Gonzalez-Duarte, WD O’Riordan, CC Yang, M Ueda, ... New England Journal of Medicine 379 (1), 11-21, 2018 | 2014 | 2018 |
| Guillain–Barré and Miller Fisher syndromes—new diagnostic classification BR Wakerley, A Uncini, N Yuki Nature Reviews Neurology 10 (9), 537-544, 2014 | 555 | 2014 |
| Phenotypic study in 40 patients with dysferlin gene mutations: high frequency of atypical phenotypes K Nguyen, G Bassez, M Krahn, R Bernard, P Laforêt, V Labelle, ... Archives of neurology 64 (8), 1176-1182, 2007 | 281 | 2007 |
| European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task … PYK Van den Bergh, PA van Doorn, RDM Hadden, B Avau, ... Journal of the Peripheral Nervous System 26 (3), 242-268, 2021 | 272 | 2021 |
| Regional variation of Guillain-Barré syndrome AY Doets, C Verboon, B Van Den Berg, T Harbo, DR Cornblath, ... Brain 141 (10), 2866-2877, 2018 | 246 | 2018 |
| Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial IN van Schaik, V Bril, N van Geloven, HP Hartung, RA Lewis, G Sobue, ... The Lancet Neurology 17 (1), 35-46, 2018 | 240 | 2018 |
| Treatment of myasthenia gravis exacerbation with intravenous immunoglobulin: a randomized double-blind clinical trial P Gajdos, C Tranchant, B Clair, F Bolgert, B Eymard, T Stojkovic, ... Archives of neurology 62 (11), 1689-1693, 2005 | 221 | 2005 |
| MUSK, a new target for mutations causing congenital myasthenic syndrome F Chevessier, B Faraut, A Ravel-Chapuis, P Richard, K Gaudon, ... Human molecular genetics 13 (24), 3229-3240, 2004 | 196 | 2004 |
| Contactin 1 IgG4 associates to chronic inflammatory demyelinating polyneuropathy with sensory ataxia Y Miura, JJ Devaux, Y Fukami, C Manso, M Belghazi, AHY Wong, N Yuki, ... Brain 138 (6), 1484-1491, 2015 | 189 | 2015 |
| Autoantibodies to nodal isoforms of neurofascin in chronic inflammatory demyelinating polyneuropathy E Delmont, C Manso, L Querol, A Cortese, A Berardinelli, A Lozza, ... Brain 140 (7), 1851-1858, 2017 | 182 | 2017 |
| Constitutive activation of the calcium sensor STIM1 causes tubular-aggregate myopathy J Böhm, F Chevessier, AM De Paula, C Koch, S Attarian, C Feger, ... The American Journal of Human Genetics 92 (2), 271-278, 2013 | 167 | 2013 |
| Effect of ascorbic acid in patients with Charcot–Marie–Tooth disease type 1A: a multicentre, randomised, double-blind, placebo-controlled trial J Micallef, S Attarian, O Dubourg, PM Gonnaud, JY Hogrel, T Stojkovic, ... The Lancet Neurology 8 (12), 1103-1110, 2009 | 151 | 2009 |
| Disrupting the right prefrontal cortex alters moral judgement S Tassy, O Oullier, Y Duclos, O Coulon, J Mancini, C Deruelle, S Attarian, ... Social cognitive and affective neuroscience 7 (3), 282-288, 2012 | 147 | 2012 |
| Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial JF Howard, V Bril, T Vu, C Karam, S Peric, T Margania, H Murai, ... The Lancet Neurology 20 (7), 526-536, 2021 | 144 | 2021 |
| An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth … S Attarian, JM Vallat, L Magy, B Funalot, PM Gonnaud, A Lacour, ... Orphanet journal of rare diseases 9, 1-15, 2014 | 141 | 2014 |
| Development of a French isometric strength normative database for adults using quantitative muscle testing JY Hogrel, CA Payan, G Ollivier, V Tanant, S Attarian, A Couillandre, ... Archives of physical medicine and rehabilitation 88 (10), 1289-1297, 2007 | 132 | 2007 |
| Multifocal motor neuropathy with and without conduction block: a single entity? E Delmont, JP Azulay, R Giorgi, S Attarian, A Verschueren, D Uzenot, ... Neurology 67 (4), 592-596, 2006 | 131 | 2006 |
| A phase II− III trial of olesoxime in subjects with amyotrophic lateral sclerosis T Lenglet, L Lacomblez, JL Abitbol, A Ludolph, JS Mora, W Robberecht, ... European journal of neurology 21 (3), 529-536, 2014 | 125 | 2014 |
| Analysis of the DYSF mutational spectrum in a large cohort of patients M Krahn, C Béroud, V Labelle, K Nguyen, R Bernard, G Bassez, ... Human mutation 30 (2), E345-E375, 2009 | 119 | 2009 |
| International Guillain‐Barré Syndrome Outcome Study: protocol of a prospective observational cohort study on clinical and biological predictors of disease course and outcome in … BC Jacobs, B van den Berg, C Verboon, G Chavada, DR Cornblath, ... Journal of the Peripheral Nervous System 22 (2), 68-76, 2017 | 111 | 2017 |
Jean-philippe Azulay在 ap-hm.fr 的电子邮件经过验证
